$46.61
00.00%
Last update: Jul 19, 4:00 PM
15 minutes delayed
Agios Pharmaceuticals reports earnings on a quarterly basis. These quarterly earnings reports give investors a glimpse into financial results from a company for a 3 month period. Earnings reports almost always include EPS and Revenue results.
Analyze the earnings history of Agios Pharmaceuticals using advanced sorting and filters.
Get Alert | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
AGIO | Agios Pharmaceuticals | -$1.51 | -$1.59 | — | — | $6.71M | $9.75M | — | — | 08/01/2024 | Get Alert |
AGIO | Agios Pharmaceuticals | -$1.47 | -$1.65 | -$1.45 | 12.12% | $5.61M | $8.37M | $8.19M | -2.16% | 05/02/2024 | Get Alert |
AGIO | Agios Pharmaceuticals | -$1.66 | -$1.65 | -$1.72 | -4.24% | $4.31M | $7.94M | $7.10M | -10.54% | 02/15/2024 | Get Alert |
AGIO | Agios Pharmaceuticals | -$1.49 | -$1.70 | -$1.64 | 3.53% | $3.52M | $7.52M | $7.40M | -1.61% | 11/02/2023 | Get Alert |
AGIO | Agios Pharmaceuticals | -$1.68 | -$1.60 | -$1.51 | 5.62% | $5.58M | $6.67M | $6.71M | 0.63% | 08/03/2023 | Get Alert |
AGIO | Agios Pharmaceuticals | -$1.74 | -$1.70 | -$1.47 | 13.53% | $832.00K | $5.23M | $5.61M | 7.25% | 05/04/2023 | Get Alert |
AGIO | Agios Pharmaceuticals | -$1.74 | -$1.62 | -$1.66 | -2.47% | $0.00 | $4.53M | $4.31M | -4.86% | 02/23/2023 | Get Alert |
AGIO | Agios Pharmaceuticals | -$1.56 | -$1.76 | -$1.49 | 15.34% | $0.00 | $5.24M | $3.52M | -32.90% | 11/03/2022 | Get Alert |
AGIO | Agios Pharmaceuticals | -$1.39 | -$1.75 | -$1.68 | 4.00% | $0.00 | $2.42M | $5.58M | 130.66% | 08/04/2022 | Get Alert |
AGIO | Agios Pharmaceuticals | -$1.31 | -$1.81 | -$1.74 | 3.87% | $0.00 | $2.71M | $832.00K | -69.30% | 05/05/2022 | Get Alert |
AGIO | Agios Pharmaceuticals | -$1.41 | -$1.69 | -$1.74 | -2.96% | $44.05M | $560.00K | $0.00 | -100.00% | 02/24/2022 | Get Alert |
AGIO | Agios Pharmaceuticals | -$1.43 | -$1.59 | -$1.56 | 1.89% | $34.71M | $2.60M | $0.00 | -100.00% | 11/03/2021 | Get Alert |
AGIO | Agios Pharmaceuticals | -$1.31 | -$1.41 | -$1.44 | -2.13% | $37.35M | $2.48M | $0.00 | -100.00% | 07/29/2021 | Get Alert |
AGIO | Agios Pharmaceuticals | -$0.59 | -$1.32 | -$1.31 | 0.76% | $87.10M | $44.60M | $0.00 | -100.00% | 04/29/2021 | Get Alert |
AGIO | Agios Pharmaceuticals | -$1.60 | -$1.33 | -$1.41 | -6.02% | $35.44M | $40.17M | $44.05M | 9.66% | 02/25/2021 | Get Alert |
AGIO | Agios Pharmaceuticals | -$1.81 | -$1.38 | -$1.43 | -3.62% | $26.02M | $38.02M | $34.71M | -8.72% | 11/05/2020 | Get Alert |
AGIO | Agios Pharmaceuticals | -$1.87 | -$1.37 | -$1.31 | 4.38% | $26.22M | $37.71M | $37.35M | -0.96% | 07/30/2020 | Get Alert |
AGIO | Agios Pharmaceuticals | -$1.59 | -$1.67 | -$0.59 | 64.67% | $30.23M | $30.83M | $87.10M | 182.51% | 04/30/2020 | Get Alert |
AGIO | Agios Pharmaceuticals | -$1.58 | -$1.72 | -$1.60 | 6.98% | $30.01M | $33.72M | $35.44M | 5.10% | 02/13/2020 | Get Alert |
AGIO | Agios Pharmaceuticals | -$1.63 | -$1.80 | -$1.81 | -0.56% | $15.20M | $32.99M | $26.02M | -21.12% | 10/31/2019 | Get Alert |
AGIO | Agios Pharmaceuticals | -$1.19 | -$1.70 | -$1.87 | -10.00% | $40.41M | $27.05M | $26.22M | -3.06% | 08/01/2019 | Get Alert |
Fiscal Quarter End | Date Reported | Actual EPS | Estimated EPS | Surprise % |
---|---|---|---|---|
Mar 2024 | 2024-05-02 | $-1.45 | $-1.65 | 12.1 % |
Dec 2023 | 2024-02-15 | $-1.72 | $-1.65 | -4.24 % |
Sep 2023 | 2023-11-02 | $-1.64 | $-1.70 | 3.53 % |
Jun 2023 | 2023-08-03 | $-1.51 | $-1.60 | 5.62 % |
Fiscal Quarter End | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
---|---|---|---|---|
Mar 2024 | 2024-05-02 | $8.19M | $8.37M | -2.16 % |
Dec 2023 | 2024-02-15 | $7.10M | $7.94M | -10.5 % |
Sep 2023 | 2023-11-02 | $7.40M | $7.52M | -1.61 % |
Jun 2023 | 2023-08-03 | $6.71M | $6.67M | 0.63 % |
Agios Pharmaceuticals (AGIO) is scheduled to report earnings on August 1, 2024. The last reported earnings were for reported on May 2, 2024 for Q1.
The Actual EPS was $-1.45, which beat the estimate of $-1.65.
The Actual Revenue was $8.2M, which missed the estimate of $8.4M.
Browse earnings estimates, EPS, and revenue on all stocks.